Results 211 to 220 of about 371,513 (350)

Cutaneous lupus erythematosus - from pathogenesis to targeted therapy. [PDF]

Nat Rev Rheumatol
Klein B, Billi AC, Abernathy-Close L, Kahlenberg JM.   +3 more
europepmc   +1 more source

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting –Adjusted Comparison to a Historical Control Group Treated With Belimumab

Arthritis &Rheumatology, EarlyView.
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo, Shu Su, Jingyue Liu, Junyu Lin, Jin Song, Zongwen Chen, Yuanyuan Peng, Lijun Jiang, Meng Jia, Li Wang, Xinhui Jiang, Wei Zhang, Zanhua Rong, Bo Zhao, Yajun Wang, Xuemei Tang   +15 more
wiley   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand?

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is characterized by a variable disease course, necessitating continuous monitoring. There is an urgent need to identify noninvasive biomarkers. By reviewing and critically assessing the quality of existing studies on LN biomarkers correlating with histopathology, we here explore the challenges in promoting their use in ...
Valentina Querin, Leonardo Palazzo, Agnes B. Fogo, Mark Haas, David R. W. Jayne, Liz Lightstone, Brad H. Rovin, Surya V. Seshan, Augusto Vaglio, Ioannis Parodis, Ingeborg M. Bajema, for the Lupus Nephritis Classification Steering Committee   +11 more
wiley   +1 more source

Lupus Enteritis: An Unusual Flare of Systemic Lupus Erythematosus. [PDF]

Cureus
Casanova Pinto J, G Costa M, Fernandes B, Ramalheira C.   +3 more
europepmc   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Systemic lupus erythematosus-associated neutrophilic dermatoses. [PDF]

JAAD Case Rep
Saeed SM, Zhou AG, Gehlhausen JR, Ko CJ, Koumpouras F, Nelson CA, Ramachandran S.   +6 more
europepmc   +1 more source

The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis

Susan Manzi, Jorge Sánchez‐Guerrero, Naoto Yokogawa, Joerg Wenzel, Josephine C Ocran-Appiah, Julia Harris, Munther A. Khamashta, Bernard Rubin, Norma Lynn Fox, Roger A. Levy, Victoria P. Werth   +10 more
openalex   +2 more sources

Asymptomatic multifocal avascular necrosis, a commonly overlooked finding in patients with systemic lupus erythematosus [PDF]

Forough Nadi, Esmat Abdollahpour, Babak Fallahi, Leila Aghaghazvini, Majid Alikhani, Mohammad Nejadhosseinian, Seyedeh Tahereh Faezi   +6 more
openalex   +1 more source

Prothrombotic Activation of Platelet Pannexin‐1 Channels in Antiphospholipid Syndrome

Arthritis &Rheumatology, EarlyView.
Objective ATP is released from platelets through both degranulation and pannexin‐1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium‐dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired ...
Bruna de Moraes Mazetto Fonseca, Somanathapura K. NaveenKumar, Srilakshmi Yalavarthi, Kavya Sugur, Thalia G. Newman, Claire K. Hoy, Cyrus Sarosh, Jordan K. Schaefer, Ajay Tambralli, Jacqueline A. Madison, Yu Zuo, Fernanda A. Orsi, Michael Holinstat, Jason S. Knight   +13 more
wiley   +1 more source